Walleye Trading’s Aldeyra Therapeutics ALDX Stock Holding History

Walleye Trading’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-100	Closed	-$1K	–	5294
2021 Q3	$1K	Buy	+100	New	+$918	﹤0.01%	5115

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Walleye Trading's ALDX Position: Q4 2021 in Review

Walleye Trading sold out of Aldeyra Therapeutics (ALDX) in Q4 2021, closing a stake of 11,489 shares — an estimated $101K sold.

Walleye Trading first reported a position in ALDX in Q2 2015 and held it in 4 quarters. The position peaked at $101K in Q3 2021. 115 funds tracked by Wall St. Rank hold ALDX as of Q4 2021.

Walleye Trading reported no remaining Aldeyra Therapeutics position as of Q4 2021 after selling out during the quarter.
Walleye Trading sold 11,489 Aldeyra Therapeutics shares in Q4 2021, an estimated $101K.
Walleye Trading first reported a position in Aldeyra Therapeutics in Q2 2015 and held it in 4 quarters.
Walleye Trading's Aldeyra Therapeutics position peaked at $101K in Q3 2021.
115 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2021.

Based on Walleye Trading's 13F filing for Q4 2021, filed 14 Feb 2022.